Webinars are approximately 60-90 minutes in length and are live-streamed on our YouTube Channel. They will also be recorded and available for later viewing.
The goal of the MedTech Innovator webinars is to provide the medtech ecosystem and our portfolio companies with feedback from experts and professionals in areas that are specific to the strategic needs outlined in our discussions and surveys. Strategic areas to be covered include: intellectual property, product development, commercialization, reimbursement, healthcare economics, regulatory strategy, clinical trial design and execution, and fundraising.
Our webinars are administered virtually and consist of one or more panelists addressing key questions supplied in advance by the MedTech Innovator Accelerator companies, as well as a general discussion on the topic within the context of the evolving healthcare ecosystem.
Ramesh is a global business leader with a consistent record of delivering growth & value-creation in pharma and medical devices in the US, Europe & Asia Pacific. He founded Alchemy Advisors in 2016, advising clients on growth strategies, investment assessment and organization design.
From Jul 2017 to Oct 2019, he served as President, International of Acelity, a world leader in wound care, where he led the business across Europe, Middle East, Africa, & Asia Pacific. 3M acquired Acelity in Oct 2019 for $6.7 Bn.
From 2011 to 2016, he served as Group President, International at Stryker (NYSE: SYK), a $15 Bn diversified medical technology company, leading Stryker’s business outside the US & Western Europe (having also led the European business from 2011-2013). He led the expansion of Stryker’s global footprint including the $750 Mn acquisition of Trauson in China, the 2nd largest MedTech deal in China.
Prior to Stryker, Ramesh served as SVP & President, Asia Pacific for Merck (NYSE: MRK) where he led a $3Bn pharma & vaccines business from 2006. He set a regional HQ in Singapore in 2007. Merck’s Asia business grew strongly under his leadership and he led the integration of Merck’s $41Bn acquisition of Schering-Plough in the region.
Before joining Merck, Ramesh held commercial & functional roles over 19 years with Sanofi & predecessor companies (Aventis, HMR, Hoechst AG), starting in 1988 with Hoechst in the US, progressing through strategic planning, finance, & global commercial roles in Germany, India & the US. During this time, he served in senior commercial roles in the US across multiple therapeutic areas and also was Managing Director of Aventis in the Indian sub-continent.
An active leader on healthcare & industry issues, Ramesh served as Chairman of PhRMA’s Asia Committee and as VP of the Indian industry trade association (OPPI). He was a founding Board member of APACMed. He was a member of the Singapore Prime Minister’s Economic Strategy subcommittee in 2009. He has served on the Boards of listed companies in India, including Laurus Labs since before its IPO, where he chaired the Audit, & Nomination & Remuneration Committees.
Ramesh is a Chartered Accountant (Institute of Chartered Accounts in England & Wales) and trained in London with Spicer & Pegler (now Deloitte) from 1983-1987. He holds a degree in Commerce &
Economics from the University of Bombay (India) & has attended a leadership program at Harvard.
Christopher Hall is the Commercial Director for Marula Health and advises healthcare companies on go-to-market strategy and commercial strategy in Asia Pacific.
Mr. Hall previously held leadership roles at global companies including Fitbit, Johnson & Johnson and Roche Diagnostics, with experience that spans more than 20 years in the healthcare and consumer industries. He holds expertise in medical devices, POCT diagnostics, and digital health. Mr. Hall also previously served as co-chair for the Healthcare Committee at The American Chamber of Commerce and has been involved with the TED organization as an organizer & panelist. He works with start-ups to develop compelling brand and investor stories. He has engaged as a speaker and panelist at various industry forums and government accelerators, including The Milken Conference, MedTech Forum and HIMSS.
Mr. Hall currently resides in Singapore, where he has lived for the last 10 years.
Shikharesh has over three decades of Med Tech sales and marketing experience with deep understanding of clinical workflows in and out of hospital. While his earlier roles with MNC’s shaped his strategic thinking in expansion into existing global markets, his later engagement with SME’s and startup’s in Singapore exposed him to challenges of working with limited resources and finding the optimum pathway to expand in new market segments. He has formally mentored more than 15 Singapore startups for commercialization.
At Ontogenix, Shikharesh is responsible for new product introduction and actionable adoption strategies for international markets. Shikharesh has worked with several MNC’s and SME’s in region to develop their global market entry strategy. He is also the first commercialization expert in Singapore’s Jumpstart program under NUS Enterprise.
In his previous life, Shikharesh held senior global strategic position with GE Healthcare for emerging markets – where he optimized new product development and introduction plans across various markets reducing impact on margins from possible overlaps. Earlier, with Philips Medical Systems, he enjoyed
great commercial success from optimizing distribution channels and developing a clear strategy for market penetration for institutional selling.
Shikharesh obtained his MBA degree from National University of Singapore and is well known in speaker circles for market entry strategies.
Edna joined Johnson & Johnson in January 2020 as Head of Media Relations, Equity and Public Affairs. Before that, she was the Head of Communications Asia at Credit Suisse, where she worked for over 13 years. There she led a team of specialists and agencies across nine markets, overseeing media relations, internal, executive, financial and crisis communications as well as digital and social media. During her tenure at the bank, she built up the communications capabilities as the business grew five-fold to a CHF 250 billion asset franchise, while expanding into new markets amidst a changing business, operating and regulatory environment.
Edna has 28 years’ corporate communications experience across Asia Pacific, in industries spanning financial services, aviation, tourism, healthcare and payments, with companies including Credit Suisse, Visa International, Parkway Group Healthcare, Cathay Pacific Airways.
Originally hailing from Hong Kong, Edna has been based in Singapore for over 20 years. She started her communications career at Cathay Pacific Airways in Hong Kong, through a period of major industrial relations as well as business and corporate identity transformations.
Jasmine Chng leads Corporate Communications for Align Technology in Asia Pacific, including Australia / New Zealand, Greater China, Japan, Korea and South Asia. In her role, she is responsible for defining and shaping Corporate Communications strategies in the Asia Pacific region for both internal and external stakeholders.
Jasmine is a seasoned global communications leader with experiences in corporate, marketing, business development and merger & acquisitions. Prior to Align Technology, she led Corporate Communications in the region at Cardinal Health, a Fortune 500 healthcare products and solutions company. In that role, she led Communications for the integration of the Cordis and Patient Recovery acquisitions from J&J and Medtronic respectively, in addition to the divestiture of its distribution business in China. Jasmine’s experience spans across Consumer, Healthcare and Technology. She has worked in the United States and across Asia in both corporate roles and agencies (Edelman, Ogilvy, Waggener Edstrom).
Aside from her role in Communications, Jasmine is also passionate about Mentorship, Diversity & Inclusion and supporting local communities. She previously held the Vice-Chair of the Communications Committee at Asia Pacific Medical Technology Association (APACMed), volunteered with Ngee Ann Polytechnic as a mentor and Daughters of Tomorrow (DOT) as a befriender. At Align, she is also the sponsor for the Singapore Employee Group that leads D&I and CSR programs.
Jasmine holds a bachelor’s degree in communications from St. Norbert College, Wisconsin, USA. She lived and worked in Boston, Chicago and Tokyo before moving back to her hometown in Singapore in 2011.
Emma Thompson founded and leads the award-winning Spurwing Communications as Managing Partner. A strategic communications specialist, she has more than 15 years’ experience advising global organisations, leadership teams and start-ups on corporate and financial relations strategies in Asia and internationally.
With a wealth of sector expertise in healthcare, food and nutrition communications, Emma is respected for the strategic counsel she provides to senior executives on reputation management, regional stakeholder engagement and capital markets communications. She has worked with many of the world’s leading organisations and innovative, high-growth companies in addition to industry associations and not-for-profits.
Emma is an active contributor to the Public Relations and Communications Association (PRCA) and sits on the Leadership committee of the British Chamber of Commerce and the Healthcare committee of the American Chamber of Commerce.
She previously co-founded Consilium Strategic Communications, was a founding member of M:Communications’ international healthcare team and a strategic communications advisor at FTI Consulting in London.
Anh Bourcet is currently Regional Director, Health Economics & Market Access, in Johnson & Johnson. In this role, Anh has been driving the Asia-Pacific strategy for Global Orthopedics, articulating and demonstrating the value of innovation, leveraging real-world evidence and access strategies. She is chair of the Asia-Pacific Medical Technology Association Digital Reimbursement Working Group & active member of the Government Affairs & Market Access Group.
Anh has about 10 years of experience with an in-depth understanding of healthcare systems in Asia-Pacific and Europe, both in the medical devices and pharmaceutical industries. Anh is passionate about patient outcomes, evidence-based medicine and innovations to improve patient care.
She started in Janssen France in Medical Affairs, then worked for the French Health Safety Agency on innovative Medical Devices. Her report and recommendations on the regulatory framework paved the way for the European Commission to build their guidelines for Innovations containing nanomaterials. She returned to Janssen Medical Affairs Asia-Pacific, when moving back to Asia, before transitioning to the Medical Device sector and to Health Economics & Market Access function.
Anh holds a PhD cum laude in Medicinal Chemistry from Paris VI & “Chimie ParisTech” Universities (France), and an Executive Master in Health Industry Management, ESSEC Business School (France). She has authored many peer-reviewed publications and spoken in various scientific and healthcare conferences.
Anand Jha is the founder and Managing Director of healthcare consulting firm, Ansea, and holds around 20yrs of multidisciplinary experience in pharmaceuticals and medical devices.
Anand’s experience ranges from sales, marketing, strategic planning, pricing & market access and general management at global, regional and local levels in Singapore, Switzerland, Russia & India. Most recently he was the Regional Head of Market Access / Government Affairs Asia as well as General Manager for Alcon Singapore. Prior to that he set-up & led the Market Access function for Novartis Oncology in Asia, where he was leading the Pricing, Market Access, Patient Relations & Communications function. Anand was instrumental in building country access teams, regional pricing & access capability, putting systems & processes in place for rapid access for pre-launch and launch brands, conceptualising and rolling-out multiple patient access programs across reimbursed, semi-reimbursed and self-pay markets and spearheading efforts to set-up regional expert forum to accelerate access for cancer drugs in Asia.
Prior to moving to Singapore in 2011, Anand was based in Basel (Switzerland) for 7yrs, working in Global Market Access & in Global Commercial Operation functions of Novartis. In his prior experience, Anand has worked for Edwards Lifesciences in Lausanne (Switzerland) and as Regional Manager for Dr. Reddy’s Labs in St Petersburg (Russia).
Anand has been an invited speaker in multiple industry and academic forums, author of publications on oncology care in academic journals and mentor to MBAs and start-ups in Medtech. Anand has a degree in Mechanical Engineering with Masters in International Business from IIFT, Delhi and MBA from IMD, Lausanne
Fabio has over 20 years of experience working with clients to diagnose, design and implement strategies and organizations in Life Sciences in Asia Pacific, Europe and the Americas
He co-leads the Healthcare practice globally for L.E.K., and serves as Executive Director of the L.E.K. APAC Life Sciences Centre of Excellence
His experience in supporting clients spans from strategy to execution, organizational development and investment support:
Business plan for new neurovascular clot retrieval device across APAC, from designing clinical development to commercialization and launch plan
Review of major medtech multinational revenues opportunity across APAC, including vascular access devices and other capital and consumables
Redesigned organization and go to market for major medtech multinational in North Asia
He earned his MBA at Kellogg School of Management, Northwestern University, and Business Administration Degree from Bocconi University in Milan
Crystal has been working in J&J over 15 years in regulatory affair industry. Crystal led different business units and group such as cardiovascular interventional device, orthopedics device, sterilization disinfection device and diagnostic reagents in JNJ China MD&D. In 2011, Crystal was transferred to J&J China R&D innovation center to support NBD & NPD development for 2 years located in Suzhou. Currently, she is regulatory supply Chain liaison with leading medical product portfolio leads in ASPAC.
Crystal is China committee member of electrical and electronic product pollution prevention standard WG, China Academy of Electronic Technology standardization of MIIT (Ministry of Industry and Information Technology) and also member of WG3 QMS in AHWP (Asian Harmonization Working Party). She used to be committee member of the National Technical Committee 136 on System of Medical Clinical Test Lab and in Vitro Diagnostic System of Standardization Administration of China.
Over 25 years of Regulatory, Quality, Clinical Trial and Pharmacovigilance experience in Asia with good knowledge in the field of Nutritional, Pharmaceuticals, Medical Devices, Consumer Healthcare and Biological products.
Externally, playing a leading role among all the Regional Regulatory professionals in AHWP (Asian Harmonization Working Party). Developed the First Asia Regulatory Affairs Certificate course since 2007 with over 3800 students in industry, government and universities. Being the founder of ARPA (Asia Regulatory Professionals Associations) since 2010 with over 4800 members. Wrote the first Asia Regulatory Book, Handbook of Medical Device Regulatory Affairs in Asia, 2nd edition now.
Adjunct Lectureship & Visiting Professorship with Nanyang Technological University (Singapore), Tohoku University (Japan), Beijing University (China), Chinese University of Hong Kong (Hong Kong), University of Hong Kong (Hong Kong), Taipei Technical University (Taiwan), University of Sydney (Australia), Dongguk University (Korea)
Arthur brings 35 years of experience in government, industry and academia, as well as a deep technical and regulatory knowledge, underpinned by a global network of relationships. He has held senior roles in the Australian Therapeutic Goods Administration (TGA) including as Director of Devices Assessment and Registration. He has provided support and training to multiple international regulatory agencies and served as adviser to the Asian Harmonization Working Party and to industry and professional bodies in Australia and internationally. Arthur’s consulting experience over two decades spans a wide range of technologies and geographies, and includes regulatory strategy, product development and testing, direct consultation with regulatory agencies, management of regulatory filings and resolution of complex and sensitive post market reviews.
Tina is considered an industry thought leader and Australian international advocate for clinical trials. She contributes to and is a pivotal member on many Australian and international clinical trial advocacy, policy and neurology focused leadership groups. Over the past 9 years, Tina has built up Neuroscience Trials Australia, a leading global specialised brand making Australia a destination for many overseas companies wanting to undertake neurology focused clinical research. This Contract Research Organisation (CRO) is globally unique and offers clients access to clinical trial sites, expertise and capabilities required to complete clinical development at global standard. Prior to her role with Neuroscience Trials Australia, Tina was the director of clinical development at Acrux Pharma Pty Ltd, a successful Australian ASX200 biotechnology company. Tina led the strategic direction, development, co-ordination and reporting of the company’s clinical programs. Tina had pivotal involvement in taking a product right through all stages of clinical development and in submission of the product dossier for US regulatory approval and subsequent out licensing of the product to one of the world’s largest pharmaceutical companies.
Tina is an expert driver of clinical drug development, particularly in the design, management and implementation of clinical trials and has worked as a clinical researcher and in senior roles within the pharmaceutical and biotechnology industry for over 25 years. Her experience encompasses all stages of drug and device development in many therapeutic areas and geographical regions.
Tina has held senior clinical positions with Kendle (now Syneos, a global CRO) that involved the leadership of projects and personnel for numerous biotechnology and pharma clients. Prior to Kendle, Tina was a post-doctoral research manager for over 10 years, responsible for a team of scientists developing new drugs for the management of diabetic disease.
Sundeep holds >20 years of extensive clinical & commercial experience in Medical Devices and CRO Industry spearheading large, complex, regulatory projects, ensuring quality deliverables on time and within budget
Well versed in strategic regulatory and/or technical consultancy to more than 100 medical device projects in various therapeutic areas
Dense experience in building and leading Asia (including China) to generate clinical evidence for regulatory approval and commercial launch of products
>10 years experience in medical device business strategy development, project management and client relationship management
Therapeutic Area expertise: Cardiovascular, Orthopaedics, Nephrology, Dermatology, Surgery & Ophthalmology
Gary Haywood is Business Development Manager for Design & Industry, Australia’s largest and leading product design and development studio. D+I’s team of over 40 designers and engineers conduct in excess of 160 development projects a year for global corporations, local enterprises and start-ups.
An experienced Product Designer and MBA, Gary has worked at the intersection of design-led innovation and business development for nearly 30 years.
Gary’s background extends across advanced and additive manufacturing to high-volume production, where he has actively managed the sourcing, technical development and commercialisation of solutions for markets from Industrial, Automotive and Construction, to Agriculture, Materials Handling and Packaging.
Previously as manager of Government program for design for business integration Design Victoria, Gary mentored senior business managers in the application of design best practice in their product, branding and digital strategies.
Yan Lin is an experienced business development professional specializing in the development of medical technologies for both mature markets and developing world applications. She has found success building businesses in the US, Europe and APAC markets. As the first local hire in the Singapore office, she built Cambridge Consultants’ medtech business in APAC over the course of 5 years. Prior experiences includes developing next generation DNA sequencing technology, molecular diagnostics, and immunoassays. With her knowledge on regulatory, reimbursement, competitive landscapes, and product development, Yan Lin is a strategic advisor on commercial and product development strategy.
Kath joined Brandon Capital Partners in 2012. Prior to this Kath was an Investment Manager with Perth based Stone Ridge Ventures, a fund manager specialising in seed-to-early stage technology investment. In addition to her investment experience Kath has start up experience in medical apps, diagnostics and fitness devices. Kath still practices as a medical doctor mainly working within the surgical field and has experience as a medical officer monitoring clinical trials. Before entering the commercial world Kath spent a few years working in clinical medicine gaining a range of experience across medical and surgical specialities and critical care. Kath is a Director of the Curtin Commercialisation Advisory Board. Kath graduated from her medical degree (MBBS) with Honours and has an MBA from the University of Western Australia. Kath is also a Graduate of the Australian Institute of Company Directors.
Dr. Burnett has a long history of biomedical device design and testing. After graduating from University of Pennsylvania’s school of Bioengineering, Dr. Burnett spent a year at the Food and Drug Administration both testing devices and writing congressional reports on the current state-of-the- art devices. Following receipt of his MD and MBA degrees from Duke University, Dr. Burnett completed his one-year internship at the Mayo Clinic in Jacksonville, FL and is currently a licensed physician in the state of California. After working for two years as a General Partner with MedVenture Associates, a medical device venture capital firm in Emeryville, CA, Dr. Burnett left the firm in 2006 and committed himself to TheraNova and its subsidiaries.
Since 2006 Dr. Burnett has raised, or helped raise, over $300MM for the 16 TheraNova spinouts including three that are commercially available in the US (one of which successfully exited in early 2020) and two available in the EU (one of which went public in the EU in 2019). He is an inventor on over 40 issued patents and over 300 patents pending worldwide. He joined University of California San Francisco as Assistant Professor and Industry Director in the Bioengineering Department in 2014. He serves as an Independent Board Member at both Siren Healthcare and UCSF HealthHub and is the founder of a non-profit, Ethonova, to develop medical devices designed for low resource areas.
Anupama Puranik is a trusted advisor to international and regional companies for succession planning, leadership search and assessment. Based in Singapore, she is a core member of the Healthcare Sector in Southeast Asia. Anu has extensive experience in executive search, with a focus on healthcare, CFO, private equity and financial services across regional and international clients.
Biten has been in Medtech R&D with 25+ years experience in leading R&D organizations, technology and innovation and Global srategies with Ip management and strategic partnerships. Passiobate driver of Digital health technologies and business model innovations.
Leadership roles in R&D at JnJ and Boston Scientific across 10+ disease platforms, business units and more than 15+ product launches and 50+ patents delivered by high performance teams.
Currently leading J&J Vision APAC R&D and collaboration with Singapore Eye Research Institute.
Aldin holds over fifteen years of experience hiring-developing high performance teams in operations, sales and marketing. Direct responsibility for profit & loss, strategy development, planning and execution, working in both P/E backed and publicly traded organizations.
George Sidis is the Managing Director of IDE Group, an organisation that loves working together with its partners to create intellectual property that new and growing businesses can be built around. George’s passion for entrepreneurship and creating new ventures has helped IDE Group work together with more than 80 organisations, ranging from early stage start-ups to large multinational corporations, providing investment, R&D and contract manufacturing services to accelerate new medical technology discovery, development and commercialisation. George is also a Non-Executive Director of Atomo Diagnostics, a company he co-founded in 2010, and prior to founding IDE Group in 2003, George worked for PricewaterhouseCoopers helping businesses fund R&D and technology commercialisation.
Joseph is the Managing Partner of Verge HealthTech Fund focusing on early stage healthcare technology companies relevant to emerging markets. Prior to this, Joseph was a scientist researching new cancer therapies, a medical device entrepreneur, and a management consultant for Oliver Wyman where he led life sciences and digital health across Asia. He has 19 scientific publications, 3 patents, and has made investments in 14 healthcare technology companies to date.
Joseph has a PhD from the University of Toronto, and an MBA from the Richard Ivey School of Business.
Laura is a CXO, investor and director. Equally strong at 10,000 foot strategic wayfinding and 1 inch operational elbow grease, she has 10 years experience navigating the complexities of taking IP-rich technologies to market. She has developed a ‘Guide on the Side’ approach, which means consultative, hands-on team enablement. Whether leading the effort or teaching others, she has a track record of comprehensive market validation, financial modeling, and fundraising. From accelerator founder & COO to Associate Professor teaching entrepreneurship and Investment Manager in venture capital, she is passionate about supporting interesting opportunities that either see the world through a unique lens or bend but not break the laws of physics.
Jimit brings over eight years of experience in healthcare innovations, deal making, corporate finance and business strategy with one of the largest healthcare providers in Asia. At HealthXCapital, Jimit is part of the Investment Team and leads deal scouting, diligence, structuring and negotiations.
Jimit has worked at Apollo Hospitals, India leading deal making, commercial and clinical diligence at Apollo Research and Innovations and worked closely with healthcare startups enabling investments and deployment. Jimit also brings significant experience in corporate finance function within the hospital, wherein he led Financial Analysis, Pricing and Costing for various services at the Hospital. Jimit brings in critical insights into the deal structuring, negotiations, go-to-market strategy and potential commercialization of startups in healthcare ecosystem.
Wei-Pu is serving as the Investment Associate at BE Capital, and managing the venture studio joined forces by BE Capital and Taipei Medical University.
Wei is focusing on digital health, medical device, the combination of AI and medical practice, and biotech. He has plentiful cross boarder investment experience and has executed investment on American, Taiwanese, and Chinese startups ranged from pre-Seed stage to C round.
Tomoko is Business Development Advisor to Nipro Corporation. She is in charge of due diligence process for a variety of investment, acquisition and partnership opportunities for Nipro. Prior to joining Nipro, Tomoko was Business Development Manager at Avantec Vascular, a U.S. subsidiary of Nipro, located in Sunnyvale, CA. She also worked for Axios International in Paris, PwC’s PRTM in its healthcare sector, and Aqumen Biopharmaceutical, a biotech start-up focused on ophthalmology. She holds an MBA from INSEAD and MS in Medicine from Kyushu University. She is a member of INSEAD angels group and HealthTech Capital angels group.
Peter leads Business Development in Asia Pacific for Johnson & Johnson Medical Device, focusing his time on seeking new opportunities and partnerships with innovative companies and institutions across the region. Prior to his Asia Pacific role, he held a number of commercial leadership roles in Australia with Johnson & Johnson before moving to the United States in an M&A role. He holds an MBA from Macquarie Graduate School of Management (MGSM), Graduate Diploma in Applied Finance and Investment from FINSIA and a Bachelor of Economics from The University of Sydney.
Florian leads Strategy and Business Development in Asia Pacific for Siemens Healthineers as well as Marketing & Sales Enablement, focusing his time on strengthening the Asian footprint for the company. He is seeking for new opportunities and partnerships with innovative companies and institutions across the region. Prior to his Asia Pacific role, he held a number of leadership roles in the areas of Marketing, Customer Services, Business Development and Strategy.
John Weiser serves as President First Run Production, Sony Pictures Television. He previously was President, U.S. distribution for Sony Pictures Television (SPT) where he oversaw all domestic sales operations for SPT, including sales of feature films produced by Sony Pictures, first-run and off-network syndicated programs and Sony Pictures library titles to U.S. broadcast networks, cable networks and television station groups along with SVOD, AVOD and domestic pay television.
Weiser also managed the personnel and operations of four regional offices located in Los Angeles, New York, Chicago, and Atlanta.
Joining the company in 1990 as account executive, west coast, Weiser became division manager in 1992. In 1995, he was promoted to vice president, west coast, managing all sales activities for the regional office. In 1999, Weiser was named senior vice president, sales for Columbia TriStar Television Distribution, expanding his duties to include sales of SPE’s vast library. With more than 500 television series and 4,000 films, it is the largest catalogue of its kind. Weiser became executive vice president, US distribution for Sony Pictures Television in 2002.
Before joining the studio, Weiser served as senior vice president, Guber-Peters Entertainment and head of sales for Chuck Barris Entertainment. His television career began at Tribune Broadcasting, where he oversaw its northeast and Midwest sales offices.
Weiser served on the board of directors of the Television Bureau of Advertising from 2004-2012. In 2006, he served on the board for the Broadcaster’s Foundation charity event. From 2003-2006, Weiser was the co-chairman of the National Association of Television Program Executives (NATPE), and from 2003-2005, he served on the fundraising steering committee board for the Cedars-Sinai Prostate Cancer Center. Weiser also served on the board of the Southern California chapter of UNICEF.
Weiser currently serves on the board of Props for Tots. For the past two years, he has served as co-Executive sponsor for SPE’s Emerging Professionals as well as a committee member for the SPE Council for Inclusion.
|JUL 15||Perfecting Your Pitch Video|
|JUL 22||MedTech M&A & Working with Strategics|
|JUL 29||Venture Capital, Term Sheets & Deal Structuring|
|AUG 5||Product Development & Manufacturing|
|AUG 12||Attracting Talent & Building Effective Advisory Boards|
|AUG 26||Industrial Design & Human Factors Engineering|
|SEPT 2||Clinical Trial Design & Management|
|SEPT 9||Regulatory Pathways in Asia Pacific|
|SEPT 16||Pricing & Reimbursement in Asia Pacific|
|SEPT 30||Social Media, PR & Brand Management|
|OCT 7||Go-To-Market Strategies: Managing Sales & Distribution|